• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by JATT Acquisition Corp (Amendment)

    1/25/24 9:53:36 AM ET
    $JATT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $JATT alert in real time by email
    SC 13G/A 1 tm243910d20_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

     

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 2 – Exit Filing)*

     

    ZURA BIO LIMITED

    (Name of Issuer)

     

    Common Stock – Class A

    (Title of Class of Securities)

     

    G50752107

    (CUSIP Number)

     

    December 31, 2023 

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

     

    ¨ Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. G50752107

     

    1    
      NAMES OF REPORTING PERSONS
         MAGNETAR FINANCIAL LLC
    2    
     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)   o
      (b)   o
    3    
      SEC USE ONLY
       
       
    4    
      CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Delaware

      5    
        SOLE VOTING POWER                 
         
        0
    NUMBER OF 6    
    SHARES   SHARED VOTING POWER             
    BENEFICIALLY    
    OWNED BY   0
    EACH 7    
    REPORTING   SOLE DISPOSITIVE POWER         
    PERSON    
    WITH:   0
      8    
        SHARED DISPOSITIVE POWER    
        0
         

    9    
     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

      
      0
    10    
      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
      o
    11    
     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     
       0.00%
    12    
      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      IA, OO

     

     

     

     

    CUSIP No.   G50752107 

     

    1    
      NAMES OF REPORTING PERSONS
         MAGNETAR CAPITAL PARTNERS LP
    2    
     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)   o
      (b)   o
    3    
      SEC USE ONLY
       
       
    4    
      CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Delaware

      5    
        SOLE VOTING POWER                 
         
        0
    NUMBER OF 6    
    SHARES   SHARED VOTING POWER             
    BENEFICIALLY    
    OWNED BY   0
    EACH 7    
    REPORTING   SOLE DISPOSITIVE POWER         
    PERSON    
    WITH:   0
      8    
        SHARED DISPOSITIVE POWER    
        0
         

    9    
     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

      
      0
    10    
      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
      o
    11    
     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     
      0.00%
    12    
      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      HC, PN

     

     

     

     

    CUSIP No.   G50752107 

     

    1    
      NAMES OF REPORTING PERSONS
         SUPERNOVA MANAGEMENT LLC
    2    
     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)   o
      (b)   o
    3    
      SEC USE ONLY
       
       
    4    
      CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Delaware

      5    
        SOLE VOTING POWER                 
         
        0
    NUMBER OF 6    
    SHARES   SHARED VOTING POWER             
    BENEFICIALLY    
    OWNED BY   0
    EACH 7    
    REPORTING   SOLE DISPOSITIVE POWER         
    PERSON    
    WITH:   0
      8    
        SHARED DISPOSITIVE POWER    
        0
         

    9    
     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

      
      0
    10    
      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
      o
    11    
      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
      0.00%
    12    
      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      HC, OO

     

     

     

     

    CUSIP No.   G50752107

     

    1    
      NAMES OF REPORTING PERSONS
         DAVID J. SNYDERMAN
    2    
     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)   o
      (b)   o
    3    
      SEC USE ONLY
       
       
    4    
      CITIZENSHIP OR PLACE OF ORGANIZATION
       
      United States of America

      5    
        SOLE VOTING POWER                 
         
        0
    NUMBER OF 6    
    SHARES   SHARED VOTING POWER             
    BENEFICIALLY    
    OWNED BY   0
    EACH 7    
    REPORTING   SOLE DISPOSITIVE POWER         
    PERSON    
    WITH:   0
      8    
        SHARED DISPOSITIVE POWER    
        0
         

    9    
      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      
      0
    10    
      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
      o
    11    
      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
      0.00%
    12    
      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      HC, IN

     

     

     

     

    SCHEDULE 13G

     

    Item 1(a)Name of Issuer.

     

    ZURA BIO LIMITED (the “Issuer”)

     

    Item 1(b)Address of Issuer’s Principal Executive Offices.

     

    1489 W. Warm Spring Rd. #110

    Henderson, NV 89014

     

    Item 2(a)Name of Person Filing.

     

    This statement is filed on behalf of each of the following person (collectively, the “Reporting Persons”):

     

    i)Magnetar Financial LLC (“Magnetar Financial”);

     

    ii)Magnetar Capital Partners LP (Magnetar Capital Partners”);

     

    iii)Supernova Management LLC (“Supernova Management”); and

     

    iv)David J. Snyderman (“Mr. Snyderman”).

     

    Magnetar Financial serves as the investment adviser to the Magnetar Funds, and as such, Magnetar Financial exercises voting and investment power over the Shares held for the Magnetar Funds’ accounts. Magnetar Capital Partners serves as the sole member and parent holding company of Magnetar Financial. Supernova Management is the general partner of Magnetar Capital Partners. The manager of Supernova Management is Mr. Snyderman.

     

    Item 2(b)Address of Principal Business Office.

     

    The address of the principal business office of each of Magnetar Financial, Magnetar Capital Partners, Supernova Management, and Mr. Snyderman is 1603 Orrington Avenue, 13th Floor, Evanston, Illinois 60201.

     

    Item 2(c)Place of Organization.

     

    i)Magnetar Financial is a Delaware limited liability company;

     

    ii)Magnetar Capital Partners is a Delaware limited partnership;

     

    iii)Supernova Management is a Delaware limited liability company; and

     

    iv)Mr. Snyderman is a citizen of the United States of America.

     

    Item 2(d)Title of Class of Securities.

     

    Common Stock

     

    Item 2(e)CUSIP Number.

     

    G50752107

     

    Item 3Reporting Person.

     

    (e) x An investment adviser in accordance with §240.13d–1(b)(1)(ii)(E)

     

    (g) x A parent holding company or control person in accordance with §240.13d–1(b)(1)(ii)(G)

     

     

     

     

    Item 4Ownership.

     

    Item 4(a)Amount Beneficially Owned:

     

    As of December 31, 2023, each of Magnetar Financial, Magnetar Capital Partners, Supernova Management and Mr. Snyderman held 0 Shares. The Shares held by the Magnetar Funds represent approximately 0.00% of the total number of Shares outstanding (calculated pursuant to Rule 13d-3(d)(1)(i)) of the outstanding shares of the Issuer).

     

    Item 4(b)Percent of Class:

     

    (i) As of December 31, 2023, each of Reporting Persons were deemed to be the beneficial owner constituting approximately 0.00% of the total number of Shares outstanding (based upon the information provided by the Issuer in its Form 10-Q filed with the SEC on November 13, 2023, there were approximately 43,593,678 Shares outstanding as of November 13, 2023).

     

    Item 4(c)Number of Shares of which such person has:

     

    Magnetar Financial, Magnetar Capital Partners, Supernova Management, and Mr. Snyderman:

     

    (i)Sole power to vote or to direct the vote: 0

     

    (ii)Shared power to vote or to direct the vote : 0

     

    (iii)Sole power to dispose or to direct the disposition of: 0

     

    (iv)Shared power to dispose or to direct the disposition of: 0

     

    Item 5Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following x.

     

    Item 6Ownership of More Than Five Percent on Behalf of Another Person.

     

    This Item 6 is not applicable.

     

    Item 7Identification and Classification of the Subsidiary which Acquired the Security Being Reported On by the Parent Holding Company.

     

    This Item 7 is not applicable.

     

    Item 8Identification and Classification of Members of the Group.

     

    This Item 8 is not applicable.

     

    Item 9Notice of Dissolution of Group.

     

    This Item 9 is not applicable.

     

     

     

     

    Item 10Certification.

     

    By signing below the Reporting Persons certifies that, to the best of their knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: January 25, 2024 magnetar financial llc
         
      By: Magnetar Capital Partners LP, its Sole Member 
      By: Supernova Management LLC, its General Partner
         
      By: /s/ Hayley A. Stein
      Name: Hayley A. Stein 
      Title: Attorney-in-fact for David J. Snyderman, Manager of Supernova Management LLC

     

    Date: January 25, 2024 magnetar capital partners LP
         
      By: Supernova Management LLC, its General Partner
         
      By: /s/ Hayley A. Stein 
      Name: Hayley A. Stein 
      Title: Attorney-in-fact for David J. Snyderman, Manager of Supernova Management LLC

     

    Date: January 25, 2024 supernova management llc
         
      By: /s/ Hayley A. Stein 
      Name: Hayley A. Stein 
      Title: Attorney-in-fact for David J. Snyderman, Manager

     

    Date: January 25, 2024 DAVID J. SNYDERMAN
         
      By: /s/ Hayley A. Stein 
      Name: Hayley A. Stein 
      Title: Attorney-in-fact for David J. Snyderman

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
    99.1   Joint Filing Agreement, dated as of January 25, 2024, among the Reporting Persons.
    99.2   Power of Attorney, dated as of December 22, 2022 filed by the Reporting Persons on January 25, 2024.

     

     

     

    Get the next $JATT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $JATT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $JATT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by JATT Acquisition Corp (Amendment)

      SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

      2/14/24 4:39:38 PM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by JATT Acquisition Corp (Amendment)

      SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

      2/14/24 9:02:53 AM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by JATT Acquisition Corp (Amendment)

      SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

      2/14/24 6:05:55 AM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JATT
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $JATT
    SEC Filings

    See more
    • Zura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp

      Zura Bio Limited to trade on Nasdaq as a clinical-stage biotechnology company focused on immunology Business combination results in approximately $65 million in gross cash proceeds to support research and development initiatives and potential future acquisitions Combined company to trade on Nasdaq under ticker "ZURA" commencing March 21, 2023 Zura Bio Limited ("Zura"), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the closing of its business combination with JATT Acquisition Corp, a special purpose acquisition company (NYSE:JATT) ("JATT"), on March 20, 2023. The business combination was

      3/21/23 6:13:00 AM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JATT Acquisition Corp Shareholders Approve Proposed Business Combination with Zura Bio Limited

      JATT Acquisition Corp (NYSE:JATT) ("JATT"), a publicly traded special purpose acquisition company, today announced that its shareholders voted to approve its proposed business combination with Zura Bio Limited ("Zura"), a clinical-stage biotechnology company. At the extraordinary general meeting of JATT's shareholders, a total of 4,907,863 ordinary shares, or 95.5% of JATT's issued and outstanding ordinary shares as of February 16, 2023, the record date of the extraordinary general meeting, were present either in person or represented by proxy. Holders of 4,903,764 ordinary shares, or 99.9% of the votes cast at the meeting, voted in favor the business combination. At the closing of the bu

      3/16/23 4:17:00 PM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JATT Acquisition Corp Announces Planned Transfer of Listing to NASDAQ in Connection with its Proposed Business Combination with Zura Bio Limited

      JATT Acquisition Corp (NYSE:JATT, JATT.WS and JATT.U))) (the "Company"), a publicly-traded special purpose acquisition company, today announced that it will voluntarily transfer the listing of its Class A ordinary shares, public warrants and units from the New York Stock Exchange ("NYSE") to the Nasdaq Stock Market LLC ("Nasdaq") in connection with, and upon the closing of, the previously announced business combination (the "Business Combination") with Zura Bio Limited, a limited company incorporated under the laws of England and Wales ("Zura"). The Company expects that listing and trading of its listed securities on the NYSE will end at market close on March 20, 2023. The Class A ordinary

      3/13/23 9:28:00 AM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JATT Acquisition Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Zura Bio Ltd (0001855644) (Filer)

      2/2/24 6:02:07 AM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JATT Acquisition Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Zura Bio Ltd (0001855644) (Filer)

      1/11/24 5:25:15 PM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JATT Acquisition Corp filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Zura Bio Ltd (0001855644) (Filer)

      1/8/24 6:03:32 AM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JATT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Lisicki Robert

      4 - Zura Bio Ltd (0001855644) (Issuer)

      1/26/24 11:33:20 AM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Ploos Van Amstel Arnout

      4 - Zura Bio Ltd (0001855644) (Issuer)

      1/26/24 11:32:02 AM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Thiara Parvinder

      4 - Zura Bio Ltd (0001855644) (Issuer)

      1/26/24 11:30:45 AM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care